Kisspeptin-10
10 mg
$73.99 CAD
Melanocortin receptor agonist · Research reagent
Also called bremelanotide, this peptide has clinical research on sexual desire in a specific female population using a defined drug formulation.
$63.99 CAD
· $6.40 / mgIn stockLot VTL-PT110102 · 99.64% purity · 10.88 mg measured
Testides · May 17, 2026 · View report · Verify
In stock · Ships next business day from Toronto
Interac e-Transfer
$9.99 shipping, free from $250 · Ships from Toronto · Canada only
Shipping and returns: Ships next business day from Toronto · $9.99 shipping, free from $250 · Arrives right or we make it right
For research use only. Not for human consumption.
Proof Line vials are filled from Align Biosciences stock under the Proof Line label. This is Align’s independent lab report for PT-141 10 mg. The report records a laboratory sample ID; a production lot number is shown when the report includes one.
PT-141, also published as Bremelanotide, is catalogued here as: Melanocortin receptor agonist. Bremelanotide is studied for sexual-desire endpoints in a defined population; receptor activity does not establish a broad performance benefit. PT-141 is bremelanotide, described as a melanocortin receptor agonist. An approved United States formulation exists with specific labelling; this listing is laboratory research material and is not that product. Also called bremelanotide, this peptide has clinical research on sexual desire in a specific female population using a defined drug formulation.
Research in this area examines melanocortin receptor signalling and sexual-desire endpoints in defined populations. Labelling for the approved formulation also documents adverse reactions and precautions.
United States labelling covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with stated exclusions, and notes that the mechanism for that indication is not fully known. Transient blood-pressure increases, nausea and hyperpigmentation are described among relevant considerations.
Official US label literature: The US indication is narrowly defined for acquired, generalized HSDD in premenopausal women; its mechanism for that indication is not fully known. The approved formulation is not this research material; US labelling is not Canadian authorization.
Official US label literature: The label reports nausea, transient blood-pressure increases and hyperpigmentation among safety considerations. The indication does not extend to performance enhancement, men or postmenopausal women.
Proof Line Peptides lists PT-141 as a vial in 10 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Toronto by tracked Canadian service.
The matched Testides report for PT-141 10 mg (report BW-PT141-10mg-050926-01, dated May 18, 2026) records 99.64% purity and 10.88 mg measured content against a 10 mg label. It documents the supplier sample sent for testing, not every shipped lot, and the original PDF is linked on this page.
Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.
10 mg
$73.99 CAD
10 mg
$89.99 CAD
10 mg
$52.99 CAD